김재덕 (가톨릭대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회1,963

가톨릭대학교 의과대학

CV File 51 kb

Emerg. Microbes Infect., Apr 15 2024, | https://doi.org/10.1080/22221751.2024.2343910 Efficacy of Genotype-matched Vaccine Against Re-emerging Genotype V Japanese Encephalitis Virus

Jae-Deog Kim^a,b*, Ah-Ra Lee^a,b*, Dah-Hyun Moon^c, Young-Uk Chung^a,b, Su-Yeon Hong^a,b, Hyo Je Cho^d, Tae Hyun Kang^e, Yo Han Jang^f, Myung Hyun Sohn^g, Baik-Lin Seong^h,i# and Sang-Uk Seo^a,b#

^aDepartment of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul, Republic of Korea;

^bDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic ofKorea;

^cThe Interdisciplinary Graduate Program in Integrative Biotechnology & Translational Medicine, Yonsei University, Incheon, Republic of Korea;

^dDepartment of Biochemistry, Chungbuk National University, Cheongju, Republic of Korea;

^eDepartment of Biopharmaceutical Chemistry, Kookmin University, Seoul, Republic of Korea;

^fDepartment of Vaccine Biotechnology, Andong National University, Andong, Republic of Korea;

^gDepartment of Pediatrics, College of Medicine, Yonsei University, Seoul 03722, Republic of Korea;

^hDepartment of Microbiologyand Immunology, College of Medicine, Yonsei University, Seoul, Republic of Korea;

ⁱVaccine Innovative Technology ALliance (VITAL)-Korea, Yonsei University, Seoul, Republic of Korea

^*These authors contributed equally to this work.

^#These corresponding authors contributed equally to this work.

Abstract

Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was conjugated with the E protein domain III of GV by genetic fusion. This GV-based vaccine antigen induced a more effective immune response in mice against GV JEV isolates compared to GIII-based antigen and efficiently protected animals from lethal challenges. Furthermore, a bivalent vaccine approach, inoculating simultaneously with GIII- and GV-based antigens, showed protective efficacy against both GIII and GV JEVs. This strategy presents a promising avenue for comprehensive protection in regions facing the threat of diverse JEV genotypes, including both prevalent GIII and GI as well as emerging GV strains.

논문정보

형식Research article
게재일2024년 04월 (BRIC 등록일 2024-04-18)
연구진국내 연구진
분야 생명과학 > 미생물학

댓글 작성 로그인

CV 열람하기

연락처 보기